Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma

References

• Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–7. doi:10.1016/S0140-6736(11)61613-9.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Fukasawa S, Oya M, Uemura H, Shinohara N, Habuchi T, Rini BI, Chen Y, Bair AH, Ozono S, et al. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study. Jpn J Clin Oncol. 2016;46(11):1031–1041. doi:10.1093/jjco/hyw103.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Tsunedomi R, Fujita Y, Otori T, Ohba M, Kawai Y, Hirata H, Matsumoto H, Haginaka J, Suzuki S, et al. Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma. Oncotarget. 2018;9(24):17160–70. doi:10.18632/oncotarget.24715.
   PubMedGoogle Scholar
• Igarashi R, Inoue T, Fujiyama N, Tsuchiya N, Numakura K, Kagaya H, Saito M, Narita S, Satoh S, Niioka T, et al. Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma. Med Oncol. 2018;35(4):51. doi:10.1007/s12032-018-1113-8.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Garcia-Donas J. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma. Pharmacogenom. 2012;13(14):1621–33. doi:10.2217/pgs.12.142.
   PubMed Web of Science ®Google Scholar
• Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos. 2011;39(5):729–35. doi:10.1124/dmd.110.037317.
   PubMed Web of Science ®Google Scholar
• Escudier B, Rini BI, Motzer RJ, Tarazi J, Kim S, Huang X, Rosbrook B, English PA, Loomis AK, Williams JA. Genotype correlations with blood pressure and efficacy from a randomized phase III trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015;13(4):328–337.e3. doi:10.1016/j.clgc.2015.02.007.
   PubMed Web of Science ®Google Scholar
• Yang R, Thomas GR, Bunting S, Ko A, Ferrara N, Keyt B, Ross J, Jin H. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol. 1996;27(6):838–44. doi:10.1097/00005344-199606000-00011.
   PubMed Web of Science ®Google Scholar
• Leon-Mateos L, Mosquera J, Anton Aparicio L. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol. 2015;6:421–5. doi:10.1016/j.redox.2015.09.007.
   PubMed Web of Science ®Google Scholar
• Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, Buring J, Hennekens CH. A prospective evaluation of an angiotensin-converting–enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med. 1995;332(11):706–712. doi:10.1056/NEJM199503163321103.
   PubMed Web of Science ®Google Scholar
• Chowdhury TA, Dronsfield MJ, Jones AF, Bain SC. Angiotensin II receptor gene polymorphisms and risk of myocardial infarction. Lancet. 1994;344(8935):1502–1503. doi:10.1016/S0140-6736(94)90318-2.
   Web of Science ®Google Scholar
• Cherney DZ, Scholey JW, Zhou J, Zimpelmann J, Kennedy C, Burns KD, Lai V, Miller JA. Endothelial nitric oxide synthase gene polymorphisms and the renal hemodynamic response to L-arginine. Kidney Int. 2009;75(3):327–32. doi:10.1038/ki.2008.574.
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, Gonzalez Del Alba A, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12(12):1143–50. doi:10.1016/S1470-2045(11)70266-2.
   PubMed Web of Science ®Google Scholar
• Numakura K, Tsuchiya N, Kagaya H, Takahashi M, Tsuruta H, Inoue T, Narita S, Huang M, Satoh S, Niioka T, et al. Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib. Anticancer Drugs. 2017;28(1):97–103. doi:10.1097/CAD.0000000000000425.
   PubMed Web of Science ®Google Scholar
• Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, et al. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2013;108(4):887–900. doi:10.1038/bjc.2012.548.
   PubMed Web of Science ®Google Scholar
• Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol. 2012;68(5):645–55. doi:10.1007/s00228-011-1171-8.
   PubMed Web of Science ®Google Scholar
• Kato H, Sassa N, Miyazaki M, Takeuchi M, Asai M, Iwai A, Noda Y, Gotoh M, Yamada K. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2016;78(4):855–62. doi:10.1007/s00280-016-3145-0.
   PubMed Web of Science ®Google Scholar
• Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, de Souza P, Xue ZG, McCann L, King KS, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011;29(18):2557–64. doi:10.1200/JCO.2010.32.9110.
   PubMed Web of Science ®Google Scholar
• Garcia-Donas J, Leandro-Garcia LJ, Gonzalez Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, et al. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. Ann Oncol. 2013;24(9):2409–14. doi:10.1093/annonc/mdt219.
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Sangalli F, Macconi D, Tomasoni S, Cattaneo I, Rizzo P, Bonandrini B, Bresciani E, Longaretti L, Gagliardini E, et al. Regression of renal disease by angiotensin II antagonism is caused by regeneration of kidney vasculature. J Am Soc Nephrol. 2015;27(3):699–705. doi:10.1681/ASN.2014100971.
   PubMed Web of Science ®Google Scholar
• Zhang G, Feenstra B, Bacelis J, Liu X, Muglia LM, Juodakis J, Miller DE, Litterman N, Jiang PP, Russell L, et al. Genetic associations with gestational duration and spontaneous preterm birth. N Engl J Med. 2017;377(12):1156–67. doi:10.1056/NEJMoa1612665.
   PubMed Web of Science ®Google Scholar
• van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ, de Jong PE. Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet. 1996;347(8994):94–95. doi:10.1016/S0140-6736(96)90213-5.
   PubMed Web of Science ®Google Scholar
• Aalto-Setala K, Wang S, Dai Y, Chen L, Dong Z, Chen Y, Li C, Zhong X, Lin W, Zhang J, et al. Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies. PloS ONE. 2013;8(9):e75285. doi:10.1371/journal.pone.0075285.
   PubMed Web of Science ®Google Scholar
• Zhang X, Lynch AI, Davis BR, Ford CE, Boerwinkle E, Eckfeldt JH, Leiendecker-Foster C, Arnett DK, Zhang W. Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PloS ONE. 2012;7(3):e34217. doi:10.1371/journal.pone.0034217.
   PubMed Web of Science ®Google Scholar
• Malhotra S, Poole J, Davis H, Dong Y, Pollock J, Snieder H, Treiber F. Effects of NOS3 Glu298Asp polymorphism on hemodynamic reactivity to stress: influences of ethnicity and obesity. Hypertens. 2004;44(6):866–71. doi:10.1161/01.HYP.0000147578.84729.ac.
   PubMed Web of Science ®Google Scholar
• McKnight AJ, Patterson CC, Sandholm N, Kilner J, Buckham TA, Parkkonen M, Forsblom C, Sadlier DM, Groop PH, Maxwell AP, et al. Genetic polymorphisms in nitric oxide synthase 3 gene and implications for kidney disease: a meta-analysis. Am J Nephrol. 2010;32(5):476–81. doi:10.1159/000321340.
   PubMed Web of Science ®Google Scholar
• Fattakhov N, Smirnova L, Atochin D, Parshukova D, Skuratovskaia D, Painter Q, Zatolokin P, Semke A, Litvinova L, Ivanova S. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and metabolic syndrome in healthy subjects and schizophrenia patients. Int J Obes (Lond). 2018;42(12):2036–46. doi:10.1038/s41366-018-0124-z.
   PubMed Web of Science ®Google Scholar
• Sladowska-Kozlowska J, Litwin M, Niemirska A, Wierzbicka A, Roszczynko M, Szperl M. Associations of the eNOS G894T gene polymorphism with target organ damage in children with newly diagnosed primary hypertension. Pediatr Nephrol. 2015;30(12):2189–97. doi:10.1007/s00467-015-3164-9.
   PubMed Web of Science ®Google Scholar
• Neves KB, Rios FJ, van der Mey L, Alves-Lopes R, Cameron AC, Volpe M, Montezano AC, Savoia C, Touyz RM. VEGFR (Vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertens. 2018;71(4):638–47. doi:10.1161/HYPERTENSIONAHA.117.10490.
   PubMed Web of Science ®Google Scholar
• Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kakinuma H, Matsuura S, Saito M, Tada H, Suzuki T, et al. Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. Transplantat. 2005;80(10):1419–24. doi:10.1097/01.tp.0000181142.82649.e3.
   PubMed Web of Science ®Google Scholar
• Numakura K, Satoh S, Tsuchiya N, Saito M, Maita S, Obara T, Tsuruta H, Inoue T, Narita S, Horikawa Y, et al. Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival. Transplantat. 2012;94(2):145–51. doi:10.1097/TP.0b013e318254391b.
   PubMed Web of Science ®Google Scholar
• Chandra S, Narang R, Sreenivas V, Bhatia J, Saluja D, Srivastava K, Mittal B. Association of angiotensin II type 1 receptor (A1166C) gene polymorphism and its increased expression in essential hypertension: a case-control study. PloS ONE. 2014;9(7):e101502. doi:10.1371/journal.pone.0101502.
   PubMed Web of Science ®Google Scholar